




Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design

Raphaël Porcher ¹, Philippe Ravaud¹, Matthieu Resche-Rigon², Pierre-Louis Tharaux ³,
Xavier Mariette⁴ and Olivier Hermine^{5,6}

¹Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS-UMR1153), INSERM/Université Paris, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Paris, France. ²Service de Biostatistique et Information Médicale, INSERM U153, Hôpital Saint Louis, AP-HP, Université de Paris, Paris, France. ³INSERM U970 Paris Cardiovascular Centre (PARCC), Université de Paris, Paris, France. ⁴Département de Rhumatologie, Hôpital Bicêtre, AP-HP, Université de Paris Sud, Paris, France. ⁵Département d'Hématologie, Hôpital Necker, AP-HP, Université de Paris, Paris, France. ⁶Laboratory of Physiopathology and Treatment of Haematological Malignancies, Institut Imagine, INSERM U1153, Université de Paris, Paris, France.

Corresponding author: Olivier Hermine (ohermine@gmail.com)



Shareable abstract (@ERSpublications)

The use of cohort multiple randomised controlled trials and epidemic crises <https://bit.ly/39Obd4N>

Cite this article as: Porcher R, Ravaud P, Resche-Rigon M, *et al.* Reply: COVID-19 drug research and the cohort multiple randomised controlled trial design. *Eur Respir J* 2022; 60: 2201187 [DOI: 10.1183/13993003.01187-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 10 June 2022
Accepted: 18 June 2022

Reply to R. Dal-Ré:

We read with interest the comment of R. Dal-Ré on the CORIMUNO-19 trials design [1–5]. The key argument is that the cohort multiple randomised controlled trial (cmRCT) design implies an alteration of the informed process that can only be justified if three requirements are fulfilled: the research has important social value, it poses no more than minimal risks to participants, and it would be impracticable to carry out without consent process modification [6]. R. Dal-Ré acknowledges that the first two requirements were fulfilled for CORIMUNO-19 trials, but argues that, given the huge number of patients hospitalised with severe or critical coronavirus disease 2019 (COVID-19) in March 2020, trials would have been feasible without consent modification.

